Acquisition of Strategic Shareholdings to Support the Regenerative Medicine-Related Business
First written in FY2021. 2 of 4 entries say "Advanced", first in FY2022. Latest entry: FY2025.
The whole theme swung hardest in 2019: 18 of 135 companies on the "Worse" side.
- FY2025SoftenedAnnual report
「Unlisted shares 2 29,750」
The policy of holding only shares that contribute to expanding the regenerative medicine-related business and enhancing corporate value remains in place, but strategically held unlisted shareholdings decreased from 3 to 2, with 1 holding sold for ¥49.992 million during the fiscal year. - FY2023AdvancedAnnual report
「Cuorips Inc. We hold these shares to maintain and strengthen a stable business relationship with the company, having entered into an outsourcing agreement for the contract processing of our cultured products to support the expansion of clinical applications and technological innovation.」
As strategically held shares contributing to the regenerative medicine-related business, we held 20,000 shares of Cuorips Inc. The acquisition cost of the unlisted shares was ¥49.992 million, bringing the number of strategically held unlisted shareholdings to 3. - FY2022AdvancedAnnual report
「The total acquisition cost related to the increase in the number of unlisted shares was ¥11.364 million, resulting from the acquisition of unlisted shares contributing to the regenerative medicine-related business.」
Under the policy of holding strategically held shares that contribute to expanding the regenerative medicine-related business and enhancing corporate value, additional unlisted shares were acquired, bringing the number of holdings to 2. - FY2021First statedAnnual report
「Our policy is to hold only strategically held shares that contribute to expanding our regenerative medicine-related business and enhancing our corporate value over the medium to long term.」
A new policy was explicitly stated to hold only strategically held shares that contribute to expanding the regenerative medicine-related business and enhancing corporate value over the medium to long term. During the fiscal year, 1 unlisted shareholding was acquired for ¥100 million.